Skip To Main Content
Wayne Kuznar on Muck Rack

Wayne Kuznar

Cleveland
As seen in: MedPage Today, HCP Live, Modern Medicine, ONCOLOGY journal, CURE Magazine, The ASCO Post, OncLive, Dermatology Times, Targeted Oncology, Urology Times and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Wayne

Contact Wayne, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Practical Issues for Pharmacists

|
By Karen Blum, Richard Reich, Meg Barbor, Wayne Kuznar
| The Oncology Pharmacist
By Sara Erickson, PharmD, BCACP; Anna Bartoo, PharmD, BCPS; Amy Wallingford, PharmD; Susan Wescott, MBA, RPh; Chelsee Jensen, PharmD, BCPS, P-RCM, RPh Biosimilars offer a significant opportunity for cost-savings yet present logistical hurdles for optimal implementation. Biosimilar savings nationwide are estimated to be $54 billion from 2017 to 2026, but these savings hinge on industry, regulatory, and policy changes to strengthen competition and sustainability in the biosimilar marketplace.
Open in Who Shared Issue with article?

Therapeutic Cancer Vaccines: The Next Frontier

|
By Patricia A. Stewart, Phoebe Starr, Wayne Kuznar, Cecile Miller
| Oncology Practice Management Verified
The landscape of cancer and immunology has gone through major scientific advances in research over the past 2 decades. The emergence of immunotherapy as a treatment option for patients diagnosed with cancer has led to improvements in patient outcomes. Patients diagnosed with certain forms of cancer can now live longer and enjoy good quality of life.
Open in Who Shared Issue with article?

Subgroup Analyses Continue to Support Investigational DLBCL Treatment

|
By Wayne Kuznar, Patricia A. Stewart
| Oncology Practice Management Verified
Subgroup analyses presented at the American Society of Hematology (ASH) Annual Meeting San Diego support the clinical benefit of brentuximab vedotin (Adcetris; Pfizer) in heavily pretreated patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Open in Who Shared Issue with article?
See all 313 licensed articles (639 Total)